Although the source of NE cells in prostate cancer is difficult to determine and more studies are needed to further clarify it in the future, neuroendocrine differentiation (NED) correlates with tumor progression, and the measurement of serum NE markers can objectively respond to the neuroendocrine differentiation of tumor cell populations, among which CgA is a widely used serum marker. The gene discussed is CGA; the disease is prostate carcinoma.